Erysaa Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Epoetin α

Indications/Uses

Anaemia associated w/ chronic renal failure in haemo- & predialysis adults & haemodialysis paed. Facilitate autologous blood collection w/in predeposit program in patients scheduled for major elective surgery.

Click to view Erysaa detailed prescribing information

Dosage/Direction for Use

IV Haemodialysis Adult & childn Correction phase: 50 IU/kg 3 times wkly, may be increased in increments of 25 IU/kg 3 times wkly for at least 4-wk intervals. Maintenance phase: Adult Recommended total wkly dose: 75-300 IU/kg. Childn >30 kg 30-100 IU/kg 3 times wkly, 10-30 kg 60-150 IU/kg 3 times wkly, <10 kg 75-100 IU/kg 3 times wkly. Autologous pre-donation program in surgery 600 IU/kg IV twice wkly for 3 wk prior to surgery. Patient who require lesser degree of erythropoietin stimulation 150-300 IU/kg twice wkly.

Click to view Erysaa detailed prescribing information

Overdosage

View Erysaa overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity to epoetin α or mammalian cell-derived products. Uncontrolled HTN. Ab-mediated pure red cell aplasia (PRCA). Patients scheduled for elective surgery & not participating in autologous blood pre-donation program who have severe coronary, peripheral arterial, carotid or cerebrovascular diseases eg, patients w/ recent MI or CVA. Surgical patients who cannot receive adequate antithrombotic prophylaxis or treatment.

Click to view Erysaa detailed prescribing information

Special Precautions

Hypersensitivity. Not to be used as IV infusion or SC inj. Not for management of anemia associated w/ hepatitis C. Discontinue use if SJS/TEN is suspected. Venous & arterial thromboses & embolism eg, DVT, pulmonary emboli, retinal thrombosis & MI; CVA eg, cerebral infarction & haemorrhage, transient ischaemic attacks. HTN; hypertensive crisis w/ encephalopathy & seizures; migraine-like headache; PRCA; epilepsy, history of seizures, conditions associated to seizure activity eg, CNS infections & brain metastases; thrombocythaemia; porphyria. Routine vol replacement in autologous pre-donation programme. Monitor Hb, BP, platelet counts & serum electrolytes regularly. Ensure adequate Fe stores & supplementation in other causes of anaemia. May affect ability to drive & use machines. Hepatic dysfunction. Chronic renal failure. Pregnancy & lactation.

Click to view Erysaa detailed prescribing information

Use In Pregnancy & Lactation

Click to view Erysaa detailed prescribing information

Adverse Reactions

URTI, nasopharyngitis, pneumonia, arteriovenous fistula site infection; diarrhoea, constipation, gastritis, upper abdominal pain & gastric haemorrhage; procedural hypotension, arteriovenous fistula site complication & thrombosis; fluid overload, hyperkalaemia; HTN, inadequately controlled BP, hypertensive crisis; pyrexia; muscle spasms; cough, rhinorrhoea; renal transplant; dizziness, cerebral infarction, intracranial haemorrhage; rash.

Click to view Erysaa detailed prescribing information

Drug Interactions

Monitor cyclosporine blood levels.

Click to view Erysaa detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Erysaa detailed prescribing information

Storage

View Erysaa storage conditions for details to ensure optimal shelf-life.

Description

View Erysaa description for details of the chemical structure and excipients (inactive components).

Action

View Erysaa mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Haematopoietic Agents / Supportive Care Therapy

ATC Classification

B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.

Regulatory Classification

Presentation/Packing

Form

Erysaa soln for inj 2,000 IU/0.5 mL

Packing/Price

6's

Form

Erysaa soln for inj 4,000 IU/0.4 mL

Packing/Price

6's

Erysaa

epoetin alfa

Manufacturer:

Duopharma (M)

Distributor:

DKSH